Relationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs.

Background: Changes in cognitive impairments and their relationship with psychopathological symptoms during treatment in schizophrenia remain debatable. Especially, there is few studies specifically focusing on female patients. Further exploration of the characteristics of female schizophrenia patients can offer valuable sex-related considerations for clinicians in diagnosis and interventions.

Abnormal network homogeneity of default-mode network and its relationships with clinical symptoms in antipsychotic-naïve first-diagnosis schizophrenia.

Schizophrenia is a severe mental disorder affecting around 0.5-1% of the global population. A few studies have shown the functional disconnection in the default-mode network (DMN) of schizophrenia patients.

Association of Reduced Local Activities in the Default Mode and Sensorimotor Networks with Clinical Characteristics in First-diagnosed Episode of Schizophrenia.

The neurodevelopmental hypothesis states that schizophrenia is a brain disease. Exploring abnormal brain activities can improve understanding of the neural pathologic mechanism of clinical characteristics and determine subjective biomarkers to differentiate patients with schizophrenia from healthy controls. We collected clinical characteristics (i.

Enhanced Prefrontal Regional Homogeneity and Its Correlations With Cognitive Dysfunction/Psychopathology in Patients With First-Diagnosed and Drug-Naive Schizophrenia.

Schizophrenia, regarded as a neurodevelopmental disorder, is characterized by positive symptoms, negative symptoms, and cognitive dysfunction. Investigating the spontaneous brain activity in patients with schizophrenia can help us understand the underlying pathophysiologic mechanism of schizophrenia. However, results concerning abnormal neural activities and their correlations with cognitive dysfunction/psychopathology of patients with schizophrenia were inconsistent.

Distinguishing Between Treatment-Resistant and Non-Treatment-Resistant Schizophrenia Using Regional Homogeneity.

Patients with treatment-resistant schizophrenia (TRS) and non-treatment-resistant schizophrenia (NTRS) respond to antipsychotic drugs differently. Previous studies demonstrated that patients with TRS or NTRS exhibited abnormal neural activity in different brain regions. Accordingly, in the present study, we tested the hypothesis that a regional homogeneity (ReHo) approach could be used to distinguish between patients with TRS and NTRS.